[go: up one dir, main page]

PE20120416A1 - Derivados de 2-piridin-2-il-pirazol-3(2h)-ona como activadores de hif y preparacion de los mismos - Google Patents

Derivados de 2-piridin-2-il-pirazol-3(2h)-ona como activadores de hif y preparacion de los mismos

Info

Publication number
PE20120416A1
PE20120416A1 PE2011001292A PE2011001292A PE20120416A1 PE 20120416 A1 PE20120416 A1 PE 20120416A1 PE 2011001292 A PE2011001292 A PE 2011001292A PE 2011001292 A PE2011001292 A PE 2011001292A PE 20120416 A1 PE20120416 A1 PE 20120416A1
Authority
PE
Peru
Prior art keywords
alkyl
pirazol
ona
pyridin
hif
Prior art date
Application number
PE2011001292A
Other languages
English (en)
Inventor
Jean-Michel Altenburger
Stephane Illiano
Valerie Fossey
Geraldine Manette
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0807474A external-priority patent/FR2940651B1/fr
Priority claimed from FR0904092A external-priority patent/FR2949466A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20120416A1 publication Critical patent/PE20120416A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R ES H, HALOGENO, HALOGENO-(ALQUILO C1-C5), -SO2-NR3R4, ENTRE OTROS; R1 ES HETEROCICLOALQUILO QUE NO CONTIENE N, -W-(CICLOALQUILO C3-C6), -W-ARILO, ENTRE OTROS; R2 ES H, -ALQUILO C1-C5, -HALOGENOALQUILO C1-C5, -W-COOR5, W-C(O)NHR5, ENTRE OTROS; W ES -ALQUILENO C1-C5 SUSTITUIDO, -CICLOALQUILENO C3-C6; R3 Y R4 SON CADA UNO H, ALQUILO C1-C5, CICLOALQUILO C3-C6, ARILO, ENTRE OTROS; R5 ES H, ALQUILO C1-C5, HALOGENOALQUILO C1-C5, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(2-CLOROBENCIL)-5-METIL-2-[5-(TRIFLUOROMETIL)PIRIDIN-2-IL]-1,2-DIHIDRO-3H-PIRAZOL-3-ONA; 6-[4-(4-CLOROBENCIL)-3-METIL-5-OXO-2,5-DIHIDRO-1H-PIRAZOL-1-IL]-N,N-DIETILPIRIDINA-3-SULFONAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE GLAUCOMAS, ENFERMEDADES RENALES, ANEMIAS, HIPERTENSION, INSUFICIENCIA CARDIACA, DIABETES, ENTRE OTROS
PE2011001292A 2008-12-29 2009-12-24 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona como activadores de hif y preparacion de los mismos PE20120416A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0807474A FR2940651B1 (fr) 2008-12-29 2008-12-29 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif
FR0904092A FR2949466A1 (fr) 2009-08-28 2009-08-28 Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif

Publications (1)

Publication Number Publication Date
PE20120416A1 true PE20120416A1 (es) 2012-05-08

Family

ID=42008610

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001292A PE20120416A1 (es) 2008-12-29 2009-12-24 Derivados de 2-piridin-2-il-pirazol-3(2h)-ona como activadores de hif y preparacion de los mismos

Country Status (35)

Country Link
US (1) US8541455B2 (es)
EP (1) EP2382205B1 (es)
JP (1) JP5734870B2 (es)
KR (1) KR20110099786A (es)
CN (1) CN102333769B (es)
AR (1) AR074915A1 (es)
AU (1) AU2009334569B2 (es)
BR (1) BRPI0924060A8 (es)
CA (1) CA2748411A1 (es)
CL (1) CL2011001496A1 (es)
CO (1) CO6400141A2 (es)
CR (1) CR20110361A (es)
CY (1) CY1115368T1 (es)
DK (1) DK2382205T3 (es)
EA (1) EA019591B1 (es)
EC (1) ECSP11011155A (es)
ES (1) ES2481042T3 (es)
HR (1) HRP20140680T1 (es)
IL (1) IL213789A (es)
MA (1) MA32976B1 (es)
MX (1) MX2011007054A (es)
MY (1) MY179093A (es)
NZ (1) NZ593751A (es)
PA (1) PA8856201A1 (es)
PE (1) PE20120416A1 (es)
PL (1) PL2382205T3 (es)
PT (1) PT2382205E (es)
SG (1) SG172803A1 (es)
SI (1) SI2382205T1 (es)
SM (1) SMT201400097B (es)
TN (1) TN2011000267A1 (es)
TW (1) TWI482763B (es)
UY (1) UY32369A (es)
WO (1) WO2010076524A2 (es)
ZA (1) ZA201104783B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA32978B1 (fr) 2008-12-29 2012-01-02 Sanofi Sa Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
JP5902671B2 (ja) * 2011-03-31 2016-04-13 キッセイ薬品工業株式会社 ベンジルピラゾール誘導体の製造方法およびその製造中間体
CN104321318A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 4-烷酰基氨基-3-吡唑啉酮衍生物
GEP201706761B (en) 2013-03-29 2017-10-25 Takeda Pharmaceuticals Co 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamide derivatives and their use as phd inhibitors
DE102016223133A1 (de) 2016-11-23 2018-05-24 Deere & Company Geschwindigkeitskontrolle einer Erntemaschine
BR112022018878A2 (pt) * 2020-03-20 2022-11-29 Akebia Therapeutics Inc Compostos, composição farmacêutica e método para tratar uma doença mediada por atividade de phd

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4023488A1 (de) * 1990-07-24 1992-01-30 Bayer Ag 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide
US5750088A (en) 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
EP1646382A4 (en) 2003-06-30 2010-07-21 Hif Bio Inc COMPOUNDS, COMPOSITIONS AND METHODS
DE102005019712A1 (de) * 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
EP2074128B1 (en) 2006-10-16 2013-08-14 Medicis Pharmaceutical Corporation Therapeutic pyrazolyl thienopyridines
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
EP2148877A2 (en) 2007-05-18 2010-02-03 Bayer Schering Pharma AG Inhibitors of hypoxia inducible factor (hif) useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Also Published As

Publication number Publication date
WO2010076524A2 (fr) 2010-07-08
MA32976B1 (fr) 2012-01-02
MY179093A (en) 2020-10-27
EP2382205A2 (fr) 2011-11-02
PL2382205T3 (pl) 2014-09-30
CL2011001496A1 (es) 2011-10-28
IL213789A (en) 2014-11-30
US20110294788A1 (en) 2011-12-01
PT2382205E (pt) 2014-07-28
AU2009334569A1 (en) 2011-07-21
HRP20140680T1 (hr) 2014-10-10
TWI482763B (zh) 2015-05-01
US8541455B2 (en) 2013-09-24
WO2010076524A3 (fr) 2010-08-26
EA019591B1 (ru) 2014-04-30
JP5734870B2 (ja) 2015-06-17
MX2011007054A (es) 2011-11-29
TN2011000267A1 (fr) 2012-12-17
SI2382205T1 (sl) 2014-08-29
JP2012513976A (ja) 2012-06-21
CN102333769A (zh) 2012-01-25
PA8856201A1 (es) 2010-07-27
KR20110099786A (ko) 2011-09-08
BRPI0924060A8 (pt) 2015-09-29
ES2481042T3 (es) 2014-07-29
DK2382205T3 (da) 2014-07-28
CR20110361A (es) 2011-09-20
ZA201104783B (en) 2012-09-26
AR074915A1 (es) 2011-02-23
TW201028391A (en) 2010-08-01
CA2748411A1 (fr) 2010-07-08
SMT201400097B (it) 2014-09-08
SG172803A1 (en) 2011-08-29
NZ593751A (en) 2013-08-30
CO6400141A2 (es) 2012-03-15
CY1115368T1 (el) 2017-01-04
CN102333769B (zh) 2014-08-27
EA201170899A1 (ru) 2012-02-28
IL213789A0 (en) 2011-07-31
UY32369A (es) 2010-07-30
EP2382205B1 (fr) 2014-04-23
BRPI0924060A2 (pt) 2015-07-07
ECSP11011155A (es) 2011-07-29
AU2009334569B2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
PE20071094A1 (es) Derivados 1-ortoflurofenil sustituidos 1,2,5-tiadiazolidindionas como inhibidores de ptpasa
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20180175A1 (es) Nuevos derivados de imidazolilmetilo 5-sustituidos
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20141191A1 (es) Compuestos como inhibidores de bace
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
PE20120416A1 (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona como activadores de hif y preparacion de los mismos
PE20110368A1 (es) Moduladores de mif
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
PE20131153A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20120403A1 (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
AR069480A1 (es) Derivados de 2-amino-pirimidina
PE20071152A1 (es) Compuestos derivados de azabiciclo[3.1.0]hex como moduladores de receptores de dopamina d3
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20140968A1 (es) Derivados de benzamida sustituida
PE20120320A1 (es) Pirazinilpirazoles
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac

Legal Events

Date Code Title Description
FC Refusal